Home > Insider Trading > Ascendis Pharma A/S

Ascendis Pharma A/S (ASND)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

News

1 - 10
Next >>

Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.

Keep Reading →

March 22nd, 2024 - Hedge Fund Investor Letters News

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.

Keep Reading →

March 17th, 2024 - Lists News

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.

Keep Reading →

March 7th, 2024 - Hedge Fund Investor Letters News

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.

Keep Reading →

February 8th, 2024 - News Transcripts

Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript

Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.

Keep Reading →

November 8th, 2023 - News Transcripts

Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here.

Keep Reading →

September 22nd, 2023 - Hedge Fund Investor Letters News

Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript

Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Keep Reading →

September 6th, 2023 - News Transcripts

Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2

Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.

Keep Reading →

August 24th, 2023 - Hedge Fund Investor Letters News

15 Worst Performing Biotech Stocks in 2023

In this article, we discuss 15 worst performing biotech stocks in 2023.

Keep Reading →

August 8th, 2023 - Hedge Funds News Stock Analysis

Here’s Why Baron Health Care Fund Harvested Ascendis Pharma A/S (ASND)

Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.

Keep Reading →

July 25th, 2023 - Hedge Fund Investor Letters News